Papanas Nikolaos, Demetzos Costas, Pippa Natassa, Maltezos Efstratios, Tentolouris Nicholas
Democritus University of Thrace, Alexandroupolis, Greece
National and Kapodistrian University of Athens, Athens, Greece.
Int J Low Extrem Wounds. 2016 Mar;15(1):63-7. doi: 10.1177/1534734616629302.
A novel heparan sulfate glycosaminoglycan mimetic product for local application to promote wound healing (CACIPLIQ) has recently become available. It is a biophysical therapeutic product comprising a polysaccharide as an innovative biomaterial to accomplish mechanical tissue engineering and skin regeneration in the site of ulceration. We present a series of 12 patients with type 2 diabetes (4 men and 8 women; age 53-87 years; diabetes duration 8-25 years) having chronic resistance to therapy for foot and lower extremity ulcerations. CACIPLIQ was locally applied twice per week after careful debridement. Complete ulcer healing was accomplished in all patients after a mean treatment duration of 4.92 months (range = 2-12 months). The product was very well tolerated. In conclusion, these results, although preliminary, are encouraging and suggest adequate efficacy and safety of the new product in difficult-to-heal foot and lower extremity ulcerations in type 2 diabetes.
一种用于局部应用以促进伤口愈合的新型硫酸乙酰肝素糖胺聚糖模拟产品（CACIPLIQ）最近已上市。它是一种生物物理治疗产品，包含一种多糖作为创新生物材料，以在溃疡部位实现机械组织工程和皮肤再生。我们报告了12例2型糖尿病患者（4名男性和8名女性；年龄53 - 87岁；糖尿病病程8 - 25年），他们对足部和下肢溃疡的治疗长期耐药。在仔细清创后，每周两次局部应用CACIPLIQ。所有患者在平均治疗4.92个月（范围 = 2 - 12个月）后均实现了溃疡完全愈合。该产品耐受性良好。总之，这些结果虽然是初步的，但令人鼓舞，并表明该新产品在2型糖尿病患者难愈合的足部和下肢溃疡中具有足够的疗效和安全性。
